12/19
12:17 pm
gpcr
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Low
Report
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
12/18
09:48 am
gpcr
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $91.00 price target on the stock.
Medium
Report
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $91.00 price target on the stock.
12/17
04:08 pm
gpcr
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity [Yahoo! Finance]
High
Report
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity [Yahoo! Finance]
12/17
04:01 pm
gpcr
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
High
Report
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
12/4
08:09 am
gpcr
Structure Therapeutics Inc. (NASDAQ: GPCR) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $80.00 price target on the stock.
Low
Report
Structure Therapeutics Inc. (NASDAQ: GPCR) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $80.00 price target on the stock.
11/22
08:00 am
gpcr
Structure Therapeutics Inc. (GPCR): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts [Yahoo! Finance]
Medium
Report
Structure Therapeutics Inc. (GPCR): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts [Yahoo! Finance]
11/15
08:30 am
gpcr
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
High
Report
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
11/13
04:05 pm
gpcr
Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights
Medium
Report
Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights
11/13
04:02 pm
gpcr
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity [Yahoo! Finance]
Medium
Report
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity [Yahoo! Finance]
11/13
04:01 pm
gpcr
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity
Medium
Report
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity
10/31
08:30 am
gpcr
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024
Medium
Report
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024
10/22
02:09 pm
gpcr
Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients [Seeking Alpha]
Low
Report
Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients [Seeking Alpha]